BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,923,675 | -16.6% | 42,951 | +0.1% | 0.02% | -10.7% |
| Q2 2023 | $3,503,723 | +3.5% | 42,922 | -5.9% | 0.03% | -6.7% |
| Q1 2023 | $3,385,661 | -8.0% | 45,635 | +2.8% | 0.03% | -16.7% |
| Q4 2022 | $3,679,706 | +20.3% | 44,398 | +312.2% | 0.04% | +12.5% |
| Q3 2022 | $3,059,000 | -19.5% | 10,772 | -1.8% | 0.03% | -13.5% |
| Q2 2022 | $3,801,000 | -19.8% | 10,965 | +0.2% | 0.04% | -2.6% |
| Q1 2022 | $4,737,000 | -13.9% | 10,938 | +2.8% | 0.04% | -9.5% |
| Q4 2021 | $5,504,000 | +4.1% | 10,640 | -2.5% | 0.04% | -2.3% |
| Q3 2021 | $5,289,000 | +7.1% | 10,914 | -0.5% | 0.04% | +7.5% |
| Q2 2021 | $4,938,000 | +15.0% | 10,966 | -2.4% | 0.04% | +5.3% |
| Q1 2021 | $4,293,000 | +20.9% | 11,239 | +0.5% | 0.04% | +18.8% |
| Q4 2020 | $3,550,000 | +24.3% | 11,180 | -3.1% | 0.03% | +14.3% |
| Q3 2020 | $2,857,000 | +25.0% | 11,533 | +33.2% | 0.03% | -12.5% |
| Q2 2020 | $2,286,000 | +34.7% | 8,656 | -3.3% | 0.03% | +10.3% |
| Q1 2020 | $1,697,000 | -64.2% | 8,947 | -58.6% | 0.03% | -49.1% |
| Q4 2019 | $4,744,000 | +2.2% | 21,612 | -8.9% | 0.06% | 0.0% |
| Q3 2019 | $4,642,000 | -19.0% | 23,723 | -13.7% | 0.06% | -13.6% |
| Q2 2019 | $5,731,000 | +6.4% | 27,487 | +1.4% | 0.07% | +3.1% |
| Q1 2019 | $5,384,000 | +37.2% | 27,118 | +0.0% | 0.06% | +28.0% |
| Q4 2018 | $3,923,000 | -28.3% | 27,106 | +1.2% | 0.05% | -3.8% |
| Q3 2018 | $5,468,000 | +41.7% | 26,791 | +2.7% | 0.05% | +33.3% |
| Q2 2018 | $3,860,000 | +0.8% | 26,087 | +2.8% | 0.04% | 0.0% |
| Q1 2018 | $3,831,000 | +9.7% | 25,366 | -5.9% | 0.04% | +14.7% |
| Q4 2017 | $3,493,000 | +36.7% | 26,966 | +27.6% | 0.03% | +9.7% |
| Q3 2017 | $2,555,000 | +38.5% | 21,133 | +34.6% | 0.03% | +19.2% |
| Q2 2017 | $1,845,000 | +17.1% | 15,700 | +1.3% | 0.03% | +18.2% |
| Q1 2017 | $1,576,000 | +6.3% | 15,500 | +7.5% | 0.02% | 0.0% |
| Q4 2016 | $1,483,000 | -18.5% | 14,420 | -13.2% | 0.02% | -21.4% |
| Q3 2016 | $1,820,000 | -2.9% | 16,620 | 0.0% | 0.03% | +7.7% |
| Q2 2016 | $1,874,000 | -2.9% | 16,620 | -18.6% | 0.03% | +4.0% |
| Q1 2016 | $1,930,000 | +11.0% | 20,420 | +5.7% | 0.02% | +8.7% |
| Q4 2015 | $1,739,000 | +10.8% | 19,320 | +13.7% | 0.02% | +4.5% |
| Q3 2015 | $1,570,000 | -26.5% | 16,985 | -26.5% | 0.02% | -12.0% |
| Q4 2014 | $2,135,000 | -2.5% | 23,107 | -1.3% | 0.02% | -7.4% |
| Q3 2014 | $2,189,000 | – | 23,407 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |